QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:INCY

Incyte (INCY) Stock Forecast, Price & News

$58.06
+0.29 (+0.50%)
(As of 10/2/2023 ET)
Compare
Today's Range
$56.82
$58.09
50-Day Range
$57.77
$65.93
52-Week Range
$56.82
$86.29
Volume
1.96 million shs
Average Volume
1.76 million shs
Market Capitalization
$13.01 billion
P/E Ratio
35.62
Dividend Yield
N/A
Price Target
$82.00

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.39 Rating Score
Upside/​Downside
41.7% Upside
$82.00 Price Target
Short Interest
Bearish
2.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.56mentions of Incyte in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.22%
From $2.98 to $3.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

50th out of 969 stocks

Commercial Physical Research Industry

2nd out of 14 stocks


INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Price History

INCY Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (INCY)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Incyte (NASDAQ:INCY) Downgraded to "Buy" at StockNews.com
Incyte Co. (NASDAQ:INCY) Receives $82.00 Consensus PT from Analysts
Truist Financial Reiterates Buy Rating for Incyte (NASDAQ:INCY)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
StockNews.com Upgrades Incyte (NASDAQ:INCY) to Strong-Buy
Incyte teams with Mia Hamm to raise GvHD awareness
JMP Securities Reaffirms Their Buy Rating on Incyte (INCY)
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
8/01/2023
Today
10/02/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,324
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$82.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+41.7%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

Net Income
$340.66 million
Pretax Margin
15.90%

Debt

Sales & Book Value

Annual Sales
$3.39 billion
Cash Flow
$2.44 per share
Book Value
$19.64 per share

Miscellaneous

Free Float
184,873,000
Market Cap
$12.97 billion
Optionable
Optionable
Beta
0.71

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Herve HoppenotMr. Herve Hoppenot (Age 63)
    CEO & Chairman
    Comp: $2.89M
  • Ms. Christiana Stamoulis MBA (Age 52)
    Exec. VP & CFO
    Comp: $1.16M
  • Ms. Maria E. Pasquale J.D.Ms. Maria E. Pasquale J.D. (Age 57)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $1.02M
  • Dr. Barry P. Flannelly M.B.A. (Age 65)
    MBA, Pharm.D., Exec. VP & GM of North America
    Comp: $996.28k
  • Dr. Steven H. Stein M.D. (Age 56)
    Exec. VP & Chief Medical Officer
    Comp: $1.22M
  • Dr. Pablo J. Cagnoni M.D. (Age 60)
    Ph.D., Pres and Head of R&D
  • Mr. Thomas Tray (Age 45)
    VP of Fin., Chief Accounting Officer & Controller
  • Mr. Michael James Morrissey (Age 59)
    Exec. VP & Head of Global Technical Operations
  • Ms. Christine Chiou
    Head of Investor Relations
  • Ms. Pamela M. Murphy (Age 72)
    VP of Investor Relations & Corp. Communications













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

18 analysts have issued 12 month target prices for Incyte's shares. Their INCY share price forecasts range from $61.00 to $100.00. On average, they predict the company's stock price to reach $82.00 in the next twelve months. This suggests a possible upside of 41.7% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the start of the year. Since then, INCY stock has decreased by 28.0% and is now trading at $57.87.
View the best growth stocks for 2023 here
.

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,480,000 shares, an increase of 13.5% from the August 31st total of 5,710,000 shares. Based on an average trading volume of 1,580,000 shares, the days-to-cover ratio is currently 4.1 days.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, August, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.08. The biopharmaceutical company had revenue of $954.61 million for the quarter, compared to analyst estimates of $920.18 million. Incyte had a trailing twelve-month return on equity of 9.25% and a net margin of 10.43%.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $57.87.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $12.97 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.63 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,324 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -